Health Care

Stocks in Concentration: Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)

0 269

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) went higher by +0.17% to close at $ 23.54. The company exchanged total volume of 24.89 million shares throughout course of last trade however it holds an average trading capacity of 30.76 million shares. Shares of company began trading at $23.32 climbed to high of $24.13 touched the low of $22.76.

The company is trading above its 50-day moving averages of 23.37 and down from 200-day moving averages of 48.13. The firm has price to book ratio of 1.43 and its price to sale ratio was 0.76.

Valeant Pharmaceuticals International, Inc.’s (VRX) has price-to-cash ratio of 6.18 and price to sale ratio of 0.76. The company net profit margin is -7.00% and gross profit margin is 75.20%. A look on the firm performance, its monthly performance is 6.81% and a quarterly performance of -29.63%. The stock price is moving up from its 20 days moving average with 8.24% and isolated negatively from 50 days moving average with -4.32%.

Valeant Pharmaceuticals International, Inc. (NYSE & TSX: VRX) and Progenics Pharmaceuticals, Inc. (PGNX) reported that the U.S. Food and Drug Administration has accepted RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Valeant expects to commence sales of RELISTOR Tablets in the U.S. in the third quarter of 2016.

“Opioid-induced constipation represents a long-lasting and potentially debilitating side effect of opioid therapy for millions of patients suffering from chronic pain,” commented Joseph C. Papa, Chief Executive Officer of Valeant. “We believe Oral RELISTOR represents a new alternative treatment for OIC, and we look forward to introducing the more convenient oral formulation as soon as practicable.”

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. 1 Month Ago,  shares have been suggested as “BUY” from “8” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 3” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “2.87” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) surged +0.14% and closed the trade at $ 7.30. The company recorded a trading capacity of 1.32 million shares below its three months average daily volume of 1.39 million shares. During the last trade, shares reached to high price of $7.47 and touched the low price of $7.24. The stock’s 50-day moving average is noted at $6.46 and its 200-day moving average is stands at $5.01.

Additionally, the company has EPS of -1.30. The company has market capitalization of $772.49M.

The average true range of Keryx Biopharmaceuticals Inc.’s (KERX) is recorded at 0.29 and the relative strength index of the stock stands 69.06. The stock price is going above to its 52 week low with 160.71% and lagging behind from its 52 week high with -25.13%. Analyst recommendation for this stock stands at 2.20. A look on the firm performance, its monthly performance is 20.66% and a quarterly performance of 42.30%. The stock price is trading upbeat from its 200 days moving average with 48.56% and up from 50 days moving average with 18.67%.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. 1 Month Ago,  shares have been suggested as “BUY” from “2” brokerage firms and recommended as “Strong Buy” by “1” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1.56” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

 

 

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

Advirtisement

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter